> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Liquidia NDA for Inhaled Treprostinil Dry Powder
- URL: https://www.fdaweb.com/liquidia-nda-for-inhaled-treprostinil-dry-powder/
- Published: 2020-04-08T12:00:00.000Z
- Updated: 2026-09-14T16:10:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146525

FDA has accepted for review a Liquidia Technologies 505(b)(2) NDA for LIQ861 (treprostinil) for treating pulmonary arterial hypertension. The inhaled dry powder formulation was designed to enhance deep-lung delivery of treprostinil through a palm-sized dry powder inhaler. The drug was developed with the company’s PRINT technology, a particle engineering platform that “enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies,” Liquidia says. The submission includes data from three clinical studies to establish the safety, tolerability and pharmacokinetic profile of LIQ861, it says. The agency has set an 11/24 user fee review action target date.